March 31, 2023
Sanofi’s PD-1 inhibitor Libtayo (cemiplimab) hit the Japanese market on March 30 for the treatment of certain patients with advanced cervical cancer, the company and partner Regeneron Pharmaceuticals said. Libtayo was approved in Japan in December and joined the NHI...read more